"10.1371_journal.pone.0012711","plos one","2010-09-15T00:00:00Z","Begoña Comin-Anduix; Hooman Sazegar; Thinle Chodon; Douglas Matsunaga; Jason Jalil; Erika von Euw; Helena Escuin-Ordinas; Robert Balderas; Bartosz Chmielowski; Jesus Gomez-Navarro; Richard C Koya; Antoni Ribas","Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America; Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America; BD Biosciences, San Jose, California, United States of America; Pfizer Global Research and Development, New London, Connecticut, United States of America","Conceived and designed the experiments: BCA BC JGN RCK AR. Performed the experiments: BCA HS TC DM JJ EvE HEO RCK. Analyzed the data: BCA HS TC DM JJ RB BC JGN RCK AR. Contributed reagents/materials/analysis tools: BCA TC RB BC JGN RCK AR. Wrote the paper: BCA AR.","Robert Balderas is an employee of BD Biosciences, the company from which the authors purchased most of the antibodies and reagents for this work. Jesus Gomez-Navarro was an employee of Pfizer Inc, the maker of tremelimumab, at the time that this research was conducted. He now works at Millennium Pharmaceuticals. Antoni Ribas has received research funding and honoraria from Pfizer Inc, the maker of tremelimumab. However, these confilcts did not influence the conduct of the research described in this manuscript, nor the adherence to the PLoS ONE policies on sharing data and materials.","2010","09","Begoña Comin-Anduix","BCA",12,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
